Antibody–drug conjugates (ADCs) is a fast moving class of targeted biotherapeutics that
currently combines the selectivity of monoclonal antibodies with the potency of a payload …

Antibody–drug conjugates (ADCs) are a promising cancer treatment modality that enables
the selective delivery of highly cytotoxic payloads to tumours. However, realizing the full …

Imidazoquinoline derivatives (IMDs) and related compounds function as synthetic agonists
of Toll-like receptors 7 and 8 (TLR7/8) and one is FDA approved for topical antiviral and skin …

Traditional antibody-drug conjugate (ADC) technology has employed tumor-targeting
antibodies to selectively deliver ultrapotent cytotoxins to tumor tissue. While this technology …

Cancer immunotherapy has emerged as a promising cancer treatment. However, its efficacy
is often limited by the immunosuppressive tumor microenvironment (TME) in solid tumors …

There is a significant amount of excitement in the scientific community around cancer
immunotherapy, as this approach has renewed hope for many cancer patients owing to …

The antibody–drug conjugate (ADC) is a well-validated modality for the cell-specific delivery
of small molecules with impact expanding rapidly beyond their originally-intended purpose …

ABSTRACT Introduction: Antibody-Drug Conjugates (ADCs) are becoming increasingly
important weapons in the fight against cancer, as evidenced by the growing number of …

Cowpea mosaic virus (CPMV) is a nucleoprotein nanoparticle that functions as a highly
potent immunomodulator when administered intratumorally and is used as an in situ …

Conspectus Recent developments in the fields of biomedical chemistry and immune
bioengineering have enabled innovative therapeutic approaches that can enhance the …